Podcast Summary: The Interview with Leslie Heaney – "Putting Diabetes Out Of Business"
Release Date: November 13, 2024
Introduction
In the episode titled "Putting Diabetes Out Of Business," host Leslie Heaney delves into the pressing issue of diabetes, particularly type 1 diabetes, coinciding with National Diabetes Awareness Month. Leslie is joined by three distinguished guests who are at the forefront of the battle against diabetes: Allison Astin, a dedicated parent and fundraiser; Dr. Natasha Leibel, director of the Pediatric Diabetes Program at Columbia University Irving Medical Center; and Lynn Starr, Chief Global Advocacy Officer at Breakthrough T1D. Together, they explore the rising prevalence of type 1 diabetes, current treatment modalities, groundbreaking research, and the crucial role of advocacy in eradicating the disease.
Rising Prevalence of Type 1 Diabetes
Leslie kicks off the conversation by highlighting the alarming increase in type 1 diabetes cases in America. She shares personal anecdotes, noting a significant rise in cases compared to her own school days. Dr. Natasha Leibel provides statistical clarity, stating, “There are about 37 million people in the country living with diabetes. About 5 to 10% of that number have type 1 diabetes, and it is on the rise” (07:33). This surge is particularly pronounced among very young children under six years old.
Understanding Type 1 vs. Type 2 Diabetes
Dr. Leibel offers a comprehensive breakdown of the differences between type 1 and type 2 diabetes. She explains that type 1 is an autoimmune condition where the body attacks pancreatic beta cells, abolishing insulin production. In contrast, type 2 diabetes involves insulin resistance despite adequate insulin levels. She emphasizes, “Developing type 1 diabetes is never anyone's fault. It does not come from ever eating too much sugar” (03:53). The conversation dispels common misconceptions, clarifying that type 1 diabetes cannot currently be prevented.
Personal Stories and Experiences
Allison Astin shares her harrowing experience of her daughter Audrey's diagnosis. She recounts the day Audrey collapsed at camp, initially misdiagnosed as having a severe stomach virus. “Within seconds, we knew it was type one. She was immediately helicoptered to pediatric ICU” (10:05). This ordeal underscored the critical need for awareness and timely diagnosis.
Lynn Starr adds her perspective, detailing her personal journey with type 1 diabetes diagnosed at 27 and her daughter Jamie's subsequent diagnosis. She highlights the emotional and logistical challenges faced by families, especially when there is no prior family history, making early detection difficult.
Current Treatment Options and Technological Advancements
Dr. Leibel outlines the current treatment landscape for type 1 diabetes, emphasizing the necessity of insulin injections or pumps. She explains the role of Continuous Glucose Monitors (CGMs) and hybrid closed-loop systems that integrate CGMs with insulin pumps to automate insulin delivery, enhancing glucose control (15:14).
Allison Astin praises these advancements, stating, “Introducing the glucose monitor alleviated a lot of the monitoring, and then the pump was life-changing” (16:31). However, she notes that despite technological strides, managing diabetes remains a relentless commitment.
Advances in Research and Potential Cures
Lynn Starr sheds light on recent breakthroughs aimed at delaying and potentially curing type 1 diabetes. She mentions the FDA-approved drug, Teplizumab, which delays the onset of type 1 diabetes by two to three years through a 14-day infusion (26:22). Furthermore, she discusses innovative cell therapies by companies like Vertex, which are progressing toward insulin independence by implanting insulin-producing cells (39:39).
Dr. Leibel emphasizes the complexity of type 1 diabetes genetics, stating, “There is not one gene that causes type 1 diabetes. There are many genes that are contributing to the risk” (24:40). This complexity makes finding a definitive cure challenging but not insurmountable.
Advocacy and Funding Efforts
Lynn Starr elaborates on Breakthrough T1D's multifaceted approach, combining funding for research and robust advocacy efforts. She highlights the organization's pivotal role in securing government funding, particularly through the Special Diabetes Program (SDP), which has contributed over $3.5 billion since its inception in 1997. Lynn advocates for a multi-year renewal of the SDP to sustain and expand critical research initiatives (33:52).
Additionally, Breakthrough T1D is actively promoting the "Screen for Type 1 Diabetes Act," aiming to secure $5 million annually for five years to enhance screening and early detection. Lynn asserts, “Early detection can prevent diabetic ketoacidosis and allow participation in clinical trials” (31:40).
Accessibility and Insurance Coverage
Ensuring access to modern diabetes management technologies is a cornerstone of Breakthrough T1D's mission. Lynn discusses the organization's efforts to secure Medicare coverage for automated insulin delivery systems, facilitating broader access: “We were able to secure Medicare coverage for automated insulin delivery systems, which was huge” (37:47). This advocacy ensures that life-changing technologies are accessible to everyone regardless of their economic status.
The Burden of Managing Type 1 Diabetes
The guests poignantly discuss the immense daily burden of managing type 1 diabetes. Allison Astin marvels at her daughter's resilience, noting, “People with type 1 diabetes... walk around and manage their diabetes while conducting their lives” (43:31). Dr. Leibel underscores the severe long-term complications of unmanaged diabetes, including blindness, amputations, and heart disease, reiterating the critical importance of effective management and the pursuit of a cure.
Calls to Action
Leslie and her guests urge listeners to take proactive steps in combating diabetes:
-
Screening: Leslie encourages those with a family history to undergo screening. Dr. Leibel supports this, stating, “I believe you should” (49:31).
-
Advocacy: Lynn Starr invites listeners to join Breakthrough T1D's advocacy efforts by signing up on their website, emphasizing the power of grassroots movements in influencing policy.
-
Support and Fundraising: Allison highlights the significance of fundraising events, such as gala nights and walkathons, to fuel research and advocacy.
Conclusion
Leslie Heaney wraps up the episode with heartfelt appreciation for her guests and reiterates the importance of collective efforts in the fight against diabetes. She emphasizes the transformative impact of research, advocacy, and community support in paving the way toward eradicating type 1 diabetes.
Notable Quotes:
- Leslie Heaney: “One in 300 Americans will develop diabetes in their lifetime...” (00:05)
- Dr. Natasha Leibel: “Developing type 1 diabetes is never anyone's fault. It does not come from ever eating too much sugar.” (03:53)
- Allison Astin: “Introducing the glucose monitor alleviated a lot of the monitoring, and then the pump was life-changing.” (16:31)
- Lynn Starr: “People with type 1 diabetes have to make, I think, the number's higher...” (43:31)
- Lynn Starr: “We were able to secure Medicare coverage for automated insulin delivery systems, which was huge.” (37:47)
Takeaways:
- Awareness: Understanding the differences between type 1 and type 2 diabetes is crucial for timely diagnosis and management.
- Advancements: Technological and medical advancements offer hope but underscore the need for continued research and funding.
- Advocacy: Collective advocacy is essential in securing necessary funding and ensuring accessibility to life-saving technologies.
- Community Support: The resilience and daily efforts of individuals managing diabetes inspire ongoing efforts toward finding a cure.
Listeners are encouraged to engage with organizations like Breakthrough T1D, participate in fundraising events, and advocate for policies that support diabetes research and accessibility.